Harpoon Therapeutics Stock Price, News & Analysis

Harpoon Therapeutics (NASDAQ: HARP) has appointed Dr. Alan Colowick to its Board of Directors, enhancing its leadership team as the company navigates pivotal clinical developments. Dr. Colowick, a seasoned biotech expert, previously held executive roles at notable companies, including Celgene and Gloucester Pharmaceuticals. His extensive experience in oncology and clinical-stage companies is expected to provide valuable insights during this growth phase. Harpoon focuses on innovative T cell engagers to treat various cancers, currently advancing multiple candidates in clinical trials.

Harpoon Therapeutics (NASDAQ: HARP) announced the publication of abstracts for three poster presentations at the AACR Annual Meeting scheduled for April 10-15, 2021. The presentations will showcase advancements in their T cell engager platform targeting various cancers, including acute myeloid leukemia and solid tumors. Notable abstracts include research on FLT3-targeting TriTACs and ProTriTAC as a modular drug platform. The full abstracts will be accessible on Harpoon's website, promising insights into innovative cancer therapies.

Harpoon Therapeutics reported a significant pipeline update on March 10, 2021, highlighting advancements in its four TriTAC clinical trials. The company confirmed a partial response for HPN424 in metastatic castration-resistant prostate cancer. Financially, Harpoon ended Q4 2020 with $150 million in cash and raised $108.1 million through a public offering. Revenue surged to $7.5 million in Q4, up from $2.2 million year-over-year. Operating expenses also increased, with a projected cash burn of $85 to $95 million for 2021.

Harpoon Therapeutics (NASDAQ: HARP) announced that Jerry McMahon, Ph.D., President and CEO, will participate in a panel discussion titled “Pushing the Envelope on Bispecific Antibodies” at the 33rd Annual Roth Conference on March 16, 2021, at 3 p.m. ET. A live audio webcast will be available in the Investors section of Harpoon Therapeutics’ website, with an archived replay following the event. The company is developing T cell engagers for treating cancer using its proprietary TriTAC platform, with several candidates in clinical trials.

Harpoon Therapeutics (NASDAQ: HARP), a clinical-stage immunotherapy company, will report its fourth quarter and full year 2020 financial results on March 10, 2021. This will be accompanied by a corporate update. The management will host a webcast and conference call at 4:30 p.m. ET/1:30 p.m. PT. Investors can access the call by dialing 866-951-6894 domestically or 409-216-0624 internationally. Harpoon is developing a novel class of T cell engagers for cancer treatment, with various products in clinical trials.

Harpoon Therapeutics (NASDAQ: HARP) announced that Dr. Gerald McMahon, CEO, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 4:20 p.m. ET. The event will be accessible via live audio webcast through the Investors section of Harpoon's website. Harpoon Therapeutics is focused on developing innovative T cell engagers to harness the immune system for cancer treatment, utilizing their TriTAC platform and currently advancing multiple clinical trials targeting various cancers.

Harpoon Therapeutics (NASDAQ: HARP) announced that the FDA granted Orphan Drug Designation for its investigational drug HPN217, targeting multiple myeloma. This significant milestone recognizes HPN217's potential in addressing unmet medical needs. The drug is part of a Phase 1/2 clinical trial, with plans for interim data presentation later this year. Orphan status offers various incentives, including tax credits and seven-year marketing exclusivity upon approval. Harpoon's pipeline also includes other drug candidates targeting various malignancies.

Harpoon Therapeutics has successfully concluded its public offering, selling 6,764,704 shares of common stock. This includes 882,352 shares from the underwriters' full exercise of their option, yielding approximately $115.0 million in gross proceeds. The offering is based on a previously filed shelf registration statement with the SEC. SVB Leerink and Piper Sandler led the offering's management.

Harpoon Therapeutics (Nasdaq: HARP) has announced the pricing of a public offering of 5,882,352 shares at $17.00 each, aiming for approximately $100 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 882,352 shares. The funds will be allocated for the clinical development of various cancer treatments, including HPN424 for prostate cancer and HPN536 for ovarian cancer, as well as for general corporate purposes. The closing is anticipated on January 11, 2021, pending customary conditions.